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Skin
Myeloid cellsInterleukin (IL)-36 cytokines belong to the IL-1 family and include three agonists, IL-36 a, b and c and one
inhibitor, IL-36 receptor antagonist (IL-36Ra). IL-36 and IL-1 (a and b) activate similar intracellular path-
ways via their related heterodimeric receptors, IL-36R/IL-1RAcP and IL-1R1/IL-1RAcP, respectively.
However, excessive IL-36 versus IL-1 signaling induces different phenotypes in humans, which may be
related to differential expression of their respective receptors.
We examined the expression of IL-36R, IL-1R1 and IL-1RAcP mRNA in human peripheral blood, tonsil
and skin immune cells by RT-qPCR. Monocyte-derived dendritic cells (MDDC), M0, M1 or M2-polarized
macrophages, primary keratinocytes, dermal macrophages and Langerhans cells (LC) were stimulated
with IL-1b or IL-36b. Cytokine production was assessed by RT-qPCR and immunoassays.
The highest levels of IL-36R mRNA were found in skin-derived keratinocytes, LC, dermal macrophages
and dermal CD1a+ DC. In the blood and in tonsils, IL-36R mRNA was predominantly found in myeloid
cells. By contrast, IL-1R1 mRNA was detected in almost all cell types with higher levels in tonsil and skin
compared to peripheral blood immune cells. IL-36b was as potent as IL-1b in stimulating M2 macro-
phages, keratinocytes and LC, less potent than IL-1b in stimulating M0 macrophages and MDDC, and
exerted no effects in M1 and dermal macrophages. Levels of IL-1Ra diminished the ability of M2 macro-
phages to respond to IL-1.
Taken together, these data are consistent with the association of excessive IL-36 signaling with an
inflammatory skin phenotype and identify human LC and M2 macrophages as new IL-36 target cells.
 2016 Elsevier Ltd. All rights reserved.1. Introduction
Interleukin (IL)-36 cytokines belong to the IL-1 family and
include three agonists, IL-36a, IL-36b and IL-36c, and one antago-
nist, IL-36 receptor antagonist (IL-36Ra). N-terminal processing of
these cytokines drastically increases their biological activities and
neutrophil proteases were recently shown to catalyze this reaction
[1,2]. IL-36 cytokines share many similarities with other IL-1 cyto-
kines. Indeed, the genes encoding IL-36 map on human chromo-
some 2 like most other IL-1 cytokine genes. IL-36 and IL-1
cytokines share a common C-terminal tertiary structure and their
N-terminal sequence is devoid of a leader peptide. IL-1 (a and b)
D. Dietrich et al. / Cytokine 84 (2016) 88–98 89and IL-36 (a, b, and c) bind to their specific membrane-bound
receptors, IL-1R1 or IL-36R, respectively, leading to the recruitment
of a common co-receptor (IL-1RAcP) and to the induction of
similar intracellular signaling pathways including NF-jB and
MAPK [3–7].
IL-36Ra shares 52% amino acid sequence with IL-1Ra, the natu-
rally occurring IL-1 inhibitor, as well as a similar inhibitory mech-
anism. Both IL-36Ra and IL-1Ra compete with agonists for their
receptor binding sites and inhibit their biological activities
[2,6,8,9]. A role for IL-36Ra in vivo is emphasized by the finding
that hereditary IL-36Ra deficiency is associated with the develop-
ment of generalized pustular psoriasis in humans [10–14] and
increased imiquimod-induced psoriasis in mice [15]. On the other
hand, IL-1Ra deficiency causes a severe clinical syndrome in
humans characterized by systemic inflammation with also skin
and bone involvement [16,17]. Concordant with this, IL-1Ra KO
mice display increased sensitivity to different models of arthritis
and may present spontaneous arthritis or psoriasis-like skin
lesions depending on the genetic background [18]. These observa-
tions indicate distinct roles for IL-1 and IL-36 despite similar sig-
naling, thus suggesting a different expression pattern of IL-1 and
IL-36 ligands and/or receptors.
The expression and biological functions of IL-1 have been well
characterized using various in vitro and in vivo experimental sys-
tems. IL-1 exerts potent pro-inflammatory actions by stimulating
innate immune cells, Th17 polarization of CD4+ T cells, the expres-
sion of adhesion molecules by endothelial cells, and contributes to
tissue damage by inducing the production of catabolic enzymes
such as matrix metalloproteinases (reviewed in [19]).
In contrast, the expression pattern and functions of IL-36 are
less well characterized. IL-36 is mainly expressed in activated
epithelia and tonsils [20], but also by macrophages [21,22],
dendritic cells (DC), CD4+ T-cells [23–26], plasma cells [27],
synovial fibroblasts [28] and keratinocytes [29,30]. In vitro-
differentiated human and mouse DC express IL-36R and respond
to IL-36 by the production of pro-inflammatory cytokines and
stimulatory co-receptors [23,25,26]. IL-36R is expressed by
mouse naïve CD4+ T cells and IL-36 induces their proliferation,
survival and polarization into interferon-c producing Th1 cells
[24]. However, IL-36R signaling is not needed for the control
of Mycobacterial and Leishmania infection in vivo, suggesting
that it is redundant for Th1 responses to pathogens [31].
Conflicting results were reported regarding IL-36R expression
in myeloid DC and monocytes from human blood [25,26]. In
mice, the microglia responds to IL-36c during experimental
autoimmune encephalitis [32].
A precise comparison of the relative effects of IL-1 and IL-36 in
human immune cells is missing. Furthermore, most of the current
knowledge regarding the effects of IL-36 on myeloid cells concerns
in vitro-derived DC, which may present different characteristics
than their ex vivo counterparts [33].
We therefore examined the expression of IL-1R1, IL-36R and
IL-1RAcP mRNA in human immune cells sorted from the periph-
eral blood, tonsils and skin. Keratinocytes were used as a posi-
tive control throughout the study because they express IL-36R
and respond vividly to IL-36 stimulation [29,34]. Our results
show that, in addition to keratinocytes, human Langerhans cells
(LC), dermal macrophages and dermal CD1a+ DC express higher
levels of IL-36R mRNA compared to blood-sorted or blood-
derived immune cells and tonsil-sorted immune cells. Most
importantly, IL-36b was as potent as IL-1b in stimulating M2-
polarized macrophages, keratinocytes and LC, inferior to IL-1b
for M0 macrophages and MDDC, and showed no effect neither
on M1 nor on dermal macrophages. We further showed that
the production of IL-1Ra by M2 macrophages impaired their
responsiveness to IL-1b.2. Material and methods
2.1. Biological reagents
Recombinant processed human IL-36a, IL-36b, IL-36c [2] and
the monoclonal mouse anti-IL-36R neutralizing antibody [5] were
generously provided by Amgen Inc. (Seattle, WA, USA). Recombi-
nant human IL-4, GM-CSF, IL-13, IFN-c and mature IL-1bwere pur-
chased from Peprotech (London, UK). The neutralizing monoclonal
mouse anti-human IL-1Ra was purchased from R&D Systems (Min-
neapolis, MN, USA) and ultrapure LPS from InvivoGen (San Diego,
CA, USA).2.2. Cell isolation and culture
Buffy coats from healthy donors were obtained from the Geneva
University Hospital Blood Bank after informed consent. Blood was
diluted 1:1 with PBS and separated on a Ficoll-Paque PLUS gradient
(GE Healthcare, Little Chalfont, UK). The layer containing periph-
eral blood mononuclear cells (PBMC) was collected and washed
twice with PBS. Cells were stained and FACS-sorted as monocytes
(CD20, CD3, CD56, CD14+), B cells (CD20+, CD3, CD56,
CD14), T cells (CD20, CD3+, CD56, CD14) or NK cells (CD20,
CD3, CD56+, CD14) on the Astrios cell-sorter (Beckman Coulter,
Brea, CA, USA) and the cell purity was over 90%.
For in vitro cell differentiation, monocytes were enriched from
PBMC by negative magnetic separation using the monocyte isola-
tion kit II and the AutoMACS pro system (both from Miltenyi Bio-
tech, Bergisch Gladbach, Germany) according to the
manufacturer’s instructions. The purity of monocytes, assessed
by CD14 cell surface expression, was over 85%. In order to generate
MDDC, monocytes were resuspended at 6.7  105 cells/mL in RPMI
glutamax (Thermo Fisher Scientific, Waltham, MA, USA), 10% FCS,
1% non-essential amino acids, 100 U/mL penicillin and 100 lg/mL
streptomycin, 1 mM sodium pyruvate, GM-CSF and IL-4 (50 ng/
mL each), and plated in culture-treated 6-well plates (Thermo
Fisher Scientific) in 3 mL/well. Alternatively, to generate unpolar-
ized macrophages (referred as M0 macrophages), monocytes were
resuspended at 2  106 cells/mL in X-vivo 10 medium (Lonza,
Basel, Switzerland), 2.5% human serum, 100 U/mL penicillin and
100 lg/mL streptomycin, 2 mM L-glutamine, and plated in non-
tissue culture-treated 6-well plates (Thermo Fisher Scientific) in
1.5 mL/well. Ultrapure LPS and IFN-c (20 ng/mL each) or IL-4 and
IL-13 (10 ng/mL each) were added at day 0 to the M0 conditions
in order to generate M1 or M2-polarized macrophages, respec-
tively. Cytokines were renewed every two days for MDDC and at
day 3 and day 7 for macrophages. At day 8, cell purity and differ-
entiation was assessed by flow cytometry. MDDC were over 80%
CD209+. M0, M1 or M2-polarized macrophages were over 90%
CD14low CD86med CD200 CD206low CD80, CD14med CD86low
CD200 CD206 CD80+ or CD14 CD86high CD200+ CD206med
CD80, respectively.
Total circulating blood DC (comprising myeloid DC1, myeloid
DC2 and plasmacytoid DC) were enriched from PBMC using blood
dendritic cell isolation kit II and the AutoMACS pro system (both
from Miltenyi) according to manufacturer’s instructions. Cell pur-
ity, defined using a FSC/SSC linear dot plot and a cocktail of anti-
bodies against CD14, BDCA1, BDCA2 and BDCA3, was over 75%.
For granulocyte isolation, fresh peripheral blood from healthy
donors was collected by venous puncture after informed consent.
Blood was diluted 1:1 with PBS and separated on a Ficoll-Paque
PLUS gradient. The granulocyte layer was collected, resuspended
in 1.5% dextran (Sigma, Buchs, Switzerland) in PBS and left 1 h at
RT. The upper phase was collected, resuspended in ice cold ery-
throcyte lysis buffer (155 mM NH4Cl, 10 mM KH2CO3, 0.1 mM
90 D. Dietrich et al. / Cytokine 84 (2016) 88–98EDTA in ddH2O) and incubated on ice for 15 min. Cells were then
washed once in PBS before further use. Cell purity assessed by
CD66b FACS staining was over 95%.
Keratinocytes, LC, dermal macrophages and dermal DC were
isolated from human skin samples resulting from cosmetic surgery
(abdominoplasty) after informed consent. For the isolation of ker-
atinocytes, the epidermis was peeled off from the dermis after
direct incubation of skin fragments in K-SFM medium supple-
mented with 10 mg/mL dispase (Thermo Fisher Scientific) over-
night at 4 C. The epidermis was then briefly digested with 0.05%
tryptase-EDTA (Thermo Fisher Scientific). Cells were resuspended
in K-SFM medium containing epidermal growth factor and pitu-
itary extract (all from Thermo Fisher Scientific) and plated in colla-
gen type V-coated dishes (Sigma). Cells were passaged at 80%
confluence and collected for further use between passages 1–4.
Alternatively, in order to isolate LC and dermal macrophages,
the epidermis was peeled off after direct incubation of skin frag-
ments in trypsin (Merck, Kenilworth, NJ, USA) 0.5% in PBS for one
hour at 37. The dermis was digested with collagenase 1 mg/mL
(Thermo Fisher Scientific) and DNAse 33.3 lg/mL (Sigma) in com-
plete medium (RPMI glutamax, 10 mM HEPES, 10% FCS, 100 U/mL
penicillin, 100 lg/mL streptomycin, 50 lg/mL Gentamicin) for
18 h at 37 C [35,36]. The cell suspension was then cultured in
complete medium for 48 h at 37 C. Cells were collected and posi-
tively enriched using anti-CD14 magnetic microbeads (Miltenyi),
before flow cytometry sorting on a FACSAria II cell-sorter (BD bio-
sciences, San Jose, CA, USA). Sorted dermal macrophages were over
90% MHCIIhigh CD14high CD86low. The epidermal fraction was
briefly treated with DNAse 0.17 mg/mL in RPMI at 37 C. The LC
in the epidermal suspension were then enriched by Ficoll-Paque
gradient separation and by positive selection with anti-CD1a mag-
netic microbeads (Miltenyi) before flow cytometry sorting. LC were
over 90% MHCIIhigh CD1a+ Langerin/CD207+.
In order to isolate emigrating dermal DC, 2 cm2 skin pieces
were placed on 40 lm cell strainers laid on complete medium in
6-well culture-treated plates (Thermo Fisher Scientific) for 4 days
[37]. Emigrating cells were then collected from the supernatant,
stained and sorted with over 90% purity as dermal CD1a+ DCs
(MHCIIhigh CD14 Langerin/CD207) or dermal CD14+ DCs
(MHCIIint CD14+ Langerin/CD207).
Tonsils were obtained from routine tonsillectomies performed
at the Ospedale San Giovanni (Bellinzona, Switzerland) after
informed consent. After mincing, tonsils were treated with 1 mg/
mL collagenase D and 1 mg/mL DNAse (Roche Diagnostics, Meylan,
France) for 60 min at 37 C. Tonsillar mononuclear cells were pre-
pared by Ficoll-Paque density centrifugation and then FACS-sorted
on a FACSAria III (Becton Dickinson, Franklin Lakes, NJ, USA) with a
purity over 97%. B cells were sorted as CD19+ CD3, CD4 T cells as
CD19 CD3+ CD4+ CD8, CD8 T cells as CD19 CD3+ CD4 CD8+
CD56, NK cells as CD19 CD3 CD4 CD8 CD56+, pDC as CD3
CD19 BDCA4+ CD11c, myeloid DC as CD3 CD19 BDCA4
CD11c+ CD14 and monocytes as CD3 CD19 BDCA4 CD11c+
CD14+.2.3. Stimulation of MDDC, polarized macrophages and skin-sorted cells
After eight days of differentiation, MDDC were detached by
pipetting, pooled and plated in fresh differentiation medium at
the concentration indicated in the figure legends. Mature IL-1b or
processed IL-36 were then added with or without pre-incubation
with the anti-IL-36R neutralizing antibody or an adequate isotype
control antibody (mouse IgG1 anti-GP3-peptibody, Amgen) at con-
centrations indicated in the figure legends. At various time-points,
supernatants were collected and cells were lyzed in Trizol reagent
(Thermo Fisher Scientific) for RNA processing.Polarized macrophages were stimulated by the addition of
100 ng/mL of mature IL-1b or processed IL-36b, either directly in
the differentiation culture without renewing medium or after de
novo plating as indicated in the figure legends. Optionally, the
anti-IL-1Ra neutralizing antibody was added at the time of stimu-
lation. At various time-points, supernatants were collected and
cells lyzed in Trizol reagent.
Primary human keratinocytes were detached using 0.05%
tryptase-EDTA and plated in K-SFM medium at 7  104 cells/mL.
LC and dermal macrophages were suspended at 5  104 and
5  105 cells/mL in complete medium, respectively. Mature IL-1b
or processed IL-36b (100 ng/mL each) were then added and super-
natants were collected 24 h later.2.4. RNA isolation and quantitative reverse transcription PCR (RT-
qPCR)
Total RNA was extracted using Trizol reagent and treated with
DNase RQ1 (Promega, Fitchburg, WI, USA) according to manufac-
turer’s instructions. Reverse transcription was performed using
superscript II reverse transcriptase (Thermo Fisher Scientific). Mes-
senger RNA levels of target genes were assessed by quantitative
PCR using SYBR green PCR mastermix (Thermo Fisher Scientific)
and specific primer pairs (Eurofins Genomics, Ebersberg, Germany)
on a Stepone Plus Real-time PCR system (Thermo Fisher Scientific).
The 2DCt method was used to determine the relative expression of
the target genes to the housekeeping gene GUSB. Each primer pair
was separated by at least one intron on the relevant genbank
sequences. The following primer sequences (50?30) were used:
IL-36R Fw-gctcccagctccggattttc Rev-gtggggcttggggtataagac, GUSB
Fw-ccaccagggaccatccaat Rev-agtcaaaatatgtgttctggacaaagtaa, IL-
1R1 Fw-cctccaggattcatcaacac Rev-aaaactccatataagggcacac, IL-
1RAcP Fw-gaccctccgtggagttttggagaa Rev-tagaacaaccaggaggcgtct,
IL-6 Fw-tgtagccgccccacacagaca Rev-ctgccagtgcctctttgctgct, TNF-a
Fw-agtgatcggcccccagaggga Rev-actggagctgcccctcagcttg, IL-12p35
Fw-gctccagaaggccagacaaa Rev-ggccaggcaactcccattag, IL-12p40
Fw-agggacatcatcaaacctgacc Rev-gctgaggtcttgtccgtgaa, IL-23p19
Fw-gtgggacacatggatctaagagaa Rev-tcagaccctggtggatcctt, IL-8 Fw-
caccggaaggaaccatctcact Rev-tgcaccttcacacagagctgc, IL-10 Fw-
gcctaacatgcttcgagatc Rev-tgatgtctgggtcttggttc.2.5. Taqman Low Density Array (TLDA)
For Supplementary Fig. 3, total RNA was extracted using the
RNeasy Mini kit (Qiagen, Valencia, CA), and cDNA synthesis was
accomplished using High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA). Custom designed TLDA
with 48 query genes and 2 control genes (HPRT and 18S rRNA)
were performed on an 7900HT Real-Time PCR System (Plate and
System from Applied Biosystems).2.6. Immunoassays
Supernatants were tested for IL-6, IL-8 (human ELISA
Ready-SET Go!, ebioscience, San Diego, CA, USA) and IL-1Ra
(human IL-1Ra Duoset ELISA kit, R&D Systems) levels by
ELISA. Alternatively, IL-6, IL-8, IL-12p70, IL-23, TNF-a and
IL-10 levels were measured by multiplex assay using the
Bioplex Magpix Multiplex reader and customized microbead and
antibody sets (Biorad, Hercules, CA, USA). For Supplementary
Fig. 3, the Human Proinflammatory II 4-plex kit (MSD,
Rockville, Maryland) was used to determine levels of IL-1b,
IL-8 and TNF-a.
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Cells were collected by pipetting or gentle scratching and
washed once in FACS buffer (1% BSA, 10 mM EDTA in PBS). Fc
receptors were blocked by incubation of 0.25  106 to 2  106 -
cells in 50 lL of 10% human serum in FACS buffer for 15 min at
4 C. Cells were then labeled with a cocktail of antibodies diluted
in FACS buffer in a total volume of 50 lL for 30 min at 4 C. Cell
viability was assessed by staining with Zombie Yellow (eBio-
science) according to manufacturer’s instructions. Data were
acquired on a Gallios 4 flow cytometer (Beckman Coulter). One
comp ebeads (ebioscience) were used for compensation. Using
Kaluza software, total cells were gated on FSC/SSC area linear
plots and doublets were excluded using FSC height/FSC area lin-
ear plots. Dead cells were counted and excluded using Zombie
Yellow histograms and cell purity and the phenotype was deter-
mined using the specific markers described in the cell isolation
and culture part.
HLA-DR-FITC, CD1a-FITC, CD1a-APC, CD11c-APC, CD14-FITC,
CD20-APC, CD80-V450, CD86-FITC, CD200-Per-CP-Cy5.5,
CD206-APC and CD209-Per-CP-Cy5.5 were from BD biosciences.
HLA-DR-PE-Cy7, CD3-FITC, CD3-PE-Cy5 and CD56-PE-Cy5 were
from Beckman-Coulter. BDCA-1-APC, BDCA-2-PE, BDCA-3-
ViobrightFITC and BDCA4-PE were from Miltenyi. CD3-PE, CD19-
PE-Cy7, CD66b-PE-Cy7 and CD86-PE were from ebiosciences.
CD4-BV421, CD56-BV421 and Zombie Yellow were from Biolegend
(San Diego, CA, USA). CD8-PE-TxRED was from Thermo Fisher
Scientific. Langerin/CD207-PE was from Dendritics (Lyon, France)
and CD14-PE from ImmunoTools (Friesoythe, Germany). For cell
sorting of skin cells, dead cells were excluded as DAPI-positive.
2.8. Statistical analysis
Unless otherwise stated in the figure legend, nP 3 and Tukey
boxplots are shown. Assuming a normal distribution, paired one-
way or two-way ANOVA were performed depending on the exper-
imental conditions. P-values are shown.Ke
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Fig. 1. Messenger RNA levels of IL-36R, IL-1R1 and IL-1RAcP in human keratino-
cytes, ex-vivo differentiated macrophages and dendritic cells and in blood-sorted
cells. Cells were isolated and cultured as described in Section 2. Total RNA was
extracted and RT-qPCR for IL-36R (A), IL-1R1 (B) and IL-1RAcP (C) were performed
using a Stepone plus Real-Time PCR system. Data were normalized against the
housekeeping gene GUSB. Tukey boxplots are represented. ND = all samples Not
Detected.3. Results
3.1. IL-36R mRNA is expressed in blood-sorted and blood-derived
human myeloid cells, though at low levels compared to keratinocytes
In order to examine the relative responsiveness of human
immune cells to IL-36 and IL-1, we first investigated the expres-
sion profile of IL-36R (Fig. 1A), IL-1R1 (1B) and IL-1RAcP (1C)
mRNA in monocytes, circulating DC, granulocytes, B-cells,
T-cells, NK cells and PBMC isolated from the peripheral blood of
healthy donors, as well as in in vitro differentiated MDDC and
M0-, M1-, and M2-polarized macrophages, while primary
keratinocytes served as a positive control. The expression of
IL-36R mRNA was restricted to the myeloid lineage, however with
much lower levels compared to keratinocytes (100-fold). In the
myeloid lineage, M0 and M2 macrophages, MDDC and
granulocytes expressed higher levels than the other tested cells.
IL-1R1 mRNA was found in all cell types with the exception of
B-cells, with noticeably higher levels in keratinocytes, M0 and
M1 macrophages, MDDC and granulocytes. IL-1RAcP mRNA was
ubiquitously expressed, although at higher levels in keratinocytes,
MDDC and granulocytes.
3.2. IL-36 stimulates human MDDC to a lesser extent than IL-1
In light of the expression profile of IL-36R, IL-1R1, and their co-
receptor IL-1RAcP mRNA in human MDDC, the stimulatory effectsof IL-36 and IL-1 were first compared in these cells. Dose-response
and time course experiments were performed to select the optimal
conditions (Supplementary Fig. 1A, B and C). All three IL-36 iso-
forms induced IL-6 production in a similar manner, with maximal
mRNA and protein levels observed after 6 h and 24 h of
92 D. Dietrich et al. / Cytokine 84 (2016) 88–98stimulation, respectively. The dose-response curve reached a pla-
teau at 100 ng/mL. The stimulatory effect of IL-36 was abrogated
when cells were pre-incubated with a neutralizing anti-IL-36R
antibody (Supplementary Fig. 1D).
Therefore, MDDC were subsequently stimulated with
100 ng/mL of IL-36b or IL-1b, and levels of IL-6, TNF-a, IL-8,
IL-12p70, IL-23 and IL-10 mRNA and proteins were measured
by RT-qPCR (Supplementary Fig. 2) or multiplex and ELISA
(Fig. 2) at 6 and 24 h, respectively. The results showed that
IL-36b significantly induced the production of some of these
cytokines, but the response was much lower than that induced
by IL-1b (10- to 100-fold).Medium IL-1
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Given their differential expression of IL-36R and IL-1R1 mRNA,
we next focused on human monocyte-derived M0, M1 and M2
macrophages. After confirming their polarization status by flow
cytometry (Fig. 3A), the cells were stimulated with IL-36b or IL-
1b (100 ng/mL each) for 24 h and IL-6 levels were measured in
the supernatant by ELISA (Fig. 3B). Both IL-1b and IL-36b induced
the production of IL-6 by M0 and M2 macrophages. IL-36b
appeared slightly more potent than IL-1b in stimulating M2macro-
phages, whereas IL-1b exerted stronger stimulatory effects on M0Medium
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inflammatory mediators (IL-1b, IL-8, TNF-a) by M2 macrophages
(Supplementary Fig. 3). Because M1 polarization conditionsinclude LPS and IFN-c, supernatants of unstimulated M1 macro-
phages contained high levels of IL-6, that neither IL-1b nor IL-36b
were able to further increase. Macrophage activation was therefore
94 D. Dietrich et al. / Cytokine 84 (2016) 88–98repeated after medium replacement (Supplementary Fig. 4). Under
these culture conditions the stimulatory effects of IL-1b tended to
increase in M2 macrophages, suggesting the presence of an IL-1b
inhibitor in the supernatant of M2 macrophages. Conversely, the
stimulatory effect of IL-1bwas visible in M1macrophages, whereas
these cells remained unresponsive to IL-36b stimulation.A
10-2
10-1
100
IL
-3
6R
 m
R
N
A
, 2
 (-
C
t)
Δ3.4. IL-1Ra impairs the response of human M2 macrophages to IL-1b
We hypothesized that the impaired response of human M2
macrophages to IL-1b seen in Fig. 3B could be related to the pres-
ence of high levels of IL-1Ra in the cell supernatant. Indeed, ele-
vated IL-1Ra levels were found in M2 macrophage cultures as
compared to M0- and M1-polarized macrophage cultures
(Fig. 4A). We therefore, stimulated M2 macrophages with IL-1b
or IL-36b (100 ng/mL each) in the absence or presence of a neutral-
izing anti-IL-1Ra antibody. As depicted in Fig. 4B, the stimulatory
effect of IL-1b, but not of IL-36b, was significantly increased upon
IL-1Ra blockade.B
10-3
ND ND NDND
100
Ke
rat
ino
cy
tes
Mo
no
cy
tes mD
C
CD
4 +
 T 
ce
lls
CD
8 +
 T 
ce
lls
NK
 ce
lls
B 
ce
lls pD
C3.5. IL-36R mRNA is detected in human myeloid DC, monocytes and
CD4+ T-cells sorted from tonsils
To extend our study to human immune cells of secondary
lymphoid organs, we isolated different cell types from human
tonsils to high purity and determined the expression of IL-36RPBS IL-1Ra
101
102
103
104
IL
-6
 c
on
ce
nt
ra
tio
n 
 (p
g/
m
l)
IL-36
IL-1
Medium
* p=0.0002
p>0.9999
p=0.9582
M0 M1 M2
0
200
400
600
800
1000
IL
-1
R
a 
co
nc
en
tr
at
io
n 
 (n
g/
m
l) * p=0.0068
* p=0.0002
* p=0.0018A
B
α
β
β
Fig. 4. IL-1Ra impairs the response of human M2 macrophages to IL-1b. Polarized
macrophages were generated as described in Section 2. On day 10, supernatants
were collected and IL-1Ra levels were measured by ELISA (A). (B) M2 macrophages
were stimulated with IL-1b or IL-36b (100 ng/mL each) in presence of a neutralizing
anti-IL-1Ra antibody 20 lg/mL or PBS. After 24 h, cell supernatants were collected
and IL-6 levels were measured by ELISA. Tukey boxplots are represented. Paired
one-way ANOVA (A) and paired two-way ANOVA (B) were performed and
respective p-values are shown.(Fig. 5A), IL-1R1 (5B) and IL-1RAcP (5C) mRNA by RT-qPCR.
Again, skin-isolated keratinocytes were used as positive control.
The expression of IL-36R mRNA was detected in the myeloid lin-
eage (monocytes and mDC) but at 10-fold lower levels compared
to keratinocytes. However, as opposed to results obtained inKe
rat
ino
cy
tes
Mo
no
cy
tes mD
C
CD
4 +
 T 
ce
lls
CD
8 +
 T 
ce
lls
NK
 ce
lls
B 
ce
lls pD
C
10-3
10-2
10-1
Ke
rat
ino
cy
tes
Mo
no
cy
tes mD
C
CD
4 +
 T 
ce
lls
CD
8 +
 T 
ce
lls
NK
 ce
lls
B 
ce
lls pD
C
10-2
10-1
100
101C
IL
-1
R
1 
m
R
N
A
, 2
 (-
C
t)
Δ
IL
-1
R
A
cP
 m
R
N
A
, 2
 (-
C
t)
Δ
Fig. 5. Messenger RNA levels of IL-36R, IL-1R1 and IL-1RAcP in human tonsil-sorted
immune cells and in keratinocytes. Cells from tonsils were isolated as described in
Section 2. Total RNA was extracted and RT-qPCR for IL-36R (A), IL-1R1 (B) and IL-
1RAcP (C) were performed using a Stepone plus Real-Time PCR system. Data were
normalized against the housekeeping gene GUSB. Tukey boxplots are represented.
ND = all samples Not Detected.
D. Dietrich et al. / Cytokine 84 (2016) 88–98 95blood where total T-cells did not express IL-36R mRNA, tonsil
CD4+ T-cells expressed IL-36R mRNA. IL-1R1 mRNA was detectedA
B
C
Ke
rat
ino
cy
tes
De
rm
al 
Ma
cro
ph
ag
es
De
rm
al 
CD
1a
 D
C
De
rm
al 
CD
14
 D
C
La
ng
erh
an
s C
ell
s
Ke
rat
ino
cy
tes
De
rm
al 
Ma
cro
ph
ag
es
De
rm
al 
CD
1a
 D
C
De
rm
al 
CD
14
 D
C
La
ng
erh
an
s C
ell
s
Ke
rat
ino
cy
tes
De
rm
al 
Ma
cro
ph
ag
es
De
rm
al 
CD
1a
 D
C
De
rm
al 
CD
14
 D
C
La
ng
erh
an
s C
ell
s
10-3
10-2
10-1
100
101
IL
-3
6R
 m
R
N
A
, 2
 (-
C
t)
10-2
10-1
100
101
IL
-1
R
A
cP
 m
R
N
A
, 2
 (-
C
t)
10-1
100
101
102
Δ
IL
-1
R
1 
m
R
N
A
, 2
  (
-
C
t)
Δ
Δ
Fig. 6. Messenger RNA levels of IL-36R, IL-1R1 and IL-1RAcP in human skin-sorted
cells and in keratinocytes. Cells from the skin were isolated as described in
Section 2. Total RNA was extracted and RT-qPCR for IL-36R (A), IL-1R1 (B) and IL-
1RAcP (C) were performed using a Stepone plus Real-Time PCR system. Data were
normalized against the housekeeping gene GUSB. Tukey boxplots are represented.in all cell types at similar levels with the exception of B-cells
and CD8+ T-cells that displayed lower transcriptional activity.
IL-1RAcP mRNA was expressed in all cell types with lower levels
in NK cells.
3.6. IL-36R mRNA is expressed at high levels in human skin immune
cells
Given the known role of IL-36 in skin inflammation [6,10,11,1
5,29,30,34,38–42], we then examined the levels of IL-36R
(Fig. 6A), IL-1R1 (6B) and IL-1RAcP (6C) mRNA in human immune
cells isolated from the skin, again in comparison with primary ker-
atinocytes. As opposed to our findings with tonsil and blood puri-
fied cells, IL-36R mRNA levels of dermal macrophages, dermal
CD1a+ DC were as high as those in keratinocytes. Even more strik-
ing, the IL-36R mRNA levels were higher in human LC. In contrast,
dermal CD14+ DC exhibited relatively low IL-36R mRNA levels. IL-
1R1 mRNA was detected in all cell types with LC again expressing
the highest levels. IL-1RAcP was ubiquitously expressed, with der-
mal CD1a+ DC expressing much lower levels than the other cell
types.
3.7. IL-1 and IL-36 exert similar effects on human keratinocytes and
LC, but not on dermal macrophages
In order to investigate their relative responses to IL-36 and IL-1,
human LC, keratinocytes, and dermal macrophages were stimu-
lated with IL-1b or IL-36b. IL-36b appeared to be as potent as IL-
1b in inducing cytokine production by LC (Fig. 7A) and ker-
atinocytes (Supplementary Fig. 5), whereas dermal macrophages
responded more potently to IL-1b stimulation (7B).4. Discussion
In the present study, we determined the expression levels of IL-
36R, IL-1R1 and IL-1RAcP by RT-qPCR in a variety of human
immune cells sorted or ex vivo differentiated from the peripheral
blood, as well as sorted from tonsils or the skin. The highest levels
of IL-36RmRNAwere found in skin immune cells, particularly in LC,
and in keratinocytes. In blood and tonsils, the expression of IL-36R
was mainly present in myeloid cells. By contrast, IL-1R1 mRNA was
detected in almost all cell types tested, with higher levels in tonsils
and skin immune cells. IL-36bwas as potent as IL-1b in stimulating
M2 macrophages, keratinocytes and LC, less potent than IL-1b in
stimulating M0 macrophages and MDDC, and exerted no effects
in M1 and dermal macrophages. IL-1Ra production by M2 macro-
phages impaired their responsiveness to IL-1b.
Several findings indicate that IL-36 is involved in skin inflam-
mation [38]. Indeed, all IL-36 isoforms are overexpressed in psori-
atic skin, including in psoriasis-like skin lesions secondary to anti-
TNF treatment [6,42]. Moreover, IL-36 induces several pro-
inflammatory mediators in human keratinocytes in vitro and is
itself induced in keratinocytes stimulated by TNF-a, IL-17, IL-22,
IFN-c or Poly(I;C) [29,30,34]. Transgenic mice overexpressing IL-
36a in keratinocytes develop psoriasis-like lesions with acanthosis,
parakeratosis, and elevated levels of psoriasis-associated cytokines
[40]. The imiquimod-induced mouse model of psoriasis is com-
pletely dependent on IL-36 and more specifically on IL-36a
[15,41]. Immunodeficient mice engrafted with human psoriatic
skin and treated with anti-IL-36R antibodies present with a very
limited pathology [39]. Our results, showing that human skin
antigen-presenting cells express high levels of IL-36R and that
human LC and keratinocytes are highly responsive to IL-36 stimu-
lation, further supports a contribution of IL-36 to skin
inflammation.
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line with a previous publication [26]. However, we demonstrate for
the first time that IL-36R is expressed by human CD4+ (but not
CD8+) T cells from tonsils. This difference may be explained by
the local microenvironment and warrant further investigations.
An interesting characteristic of macrophages is their ability to
‘‘switch” from a phenotype to another in vitro and in vivo [43–
45], suggesting that a given cell may participate sequentially in
both the induction and the resolution of inflammation [46]. These
functions are attributed to specific macrophage activation states
[47], including the pro-inflammatory M1 (or classically activated
Macrophages, induced by LPS + IFN-c) and the anti-inflammatory
M2 (or alternatively activated Macrophages, induced by IL-4)
states. In our study, levels of IL-36R mRNA were higher in human
M2 than in M1 macrophages, whereas a reverse pattern was
observed for IL-1R1, suggesting that M2 macrophages may be a
potential target cell for IL-36 stimulation. Indeed, we observed that
IL-36b was slightly more potent than IL-1b in inducing IL-6 pro-
duction by M2 but not by M1 or M0 macrophages. Moreover, IL-
36b was also able to stimulate M2 macrophages to produce IL-
1b, IL-8 and TNF-a, turning these cells towards a more pro-
inflammatory state. Interestingly, in vitro polarized M2 macro-
phages express also high levels of IL-1Ra leading to attenuated
IL-1b responses and potentially with an anti-inflammatory
phenotype.
It should be emphasized that in addition to immune cells, many
other cell types, including stromal cells and endothelial cells could
contribute to the differences in clinical manifestations associated
with excessive IL-1 and IL-36 signaling in humans. In a previousstudy, we compared the effects of IL-1b and IL-36b in human syn-
ovial fibroblasts and observed that IL-1b was a much more potent
inducer of cytokine responses than IL-36b (GP, CG, unpublished
data). Consistent with these findings, IL-1 plays a critical role in
several experimental models of arthritis, whereas IL-36 has no
effect [48].
One limit to our study is that levels of IL-36R and IL-1R1 mRNA
in a particular cell-type are not predictive of its relative response to
IL-36 and IL-1. Indeed, dermal macrophages express high levels of
both IL-36R and IL-1R1 mRNA, but respond only to IL-1b. The same
was observed for granulocytes (data not shown). It is plausible that
IL-36 mRNA levels do not properly reflect cell surface receptor
levels, thus explaining this discrepancy. Unfortunately, we were
unable to confirm this hypothesis because, in our hands, the pres-
ence of endogenous IL-36R in human primary cells was not reliably
detectable by flow cytometry. Thus, our findings indicate that there
is only a partial correlation between the mRNA levels of IL-36R and
IL-1R1 and cell responses to IL-36 and IL-1. Another hypothesis to
explain the lack of responsiveness to IL-36 could be related to ele-
vated levels of IL-36Ra in cell supernatants. However, this appears
unlikely in the case of dermal macrophages and granulocytes,
because medium renewal was performed prior stimulation. Finally,
the absence of IL-1RAcP or downstream signaling molecules is
unlikely since it would theoretically impact the effects of both IL-
1 and IL-36.
Quantitative differences may exist in the stimulatory effects
elicited by IL-36a, IL-36b and IL-36c. In Supplementary Fig. 1, we
have shown that all IL-36 agonists are equipotent in inducing IL-
6 production by MDDC. Regarding the other cell types, IL-36b
D. Dietrich et al. / Cytokine 84 (2016) 88–98 97was recently shown to be at least as potent as IL-36a and IL-36c in
inducing cytokine production by monocytes and in maturating
mDC [26]. Concerning skin cells, IL-36b was shown in different
studies to be the most effective IL-36 agonist in inducing the
production of cytokines, chemokines and metalloproteinases by
human keratinocytes [29,34] and epidermal cell cultures [34].
Finally, IL-36b is at least as produced as the other IL-36 agonists by
human keratinocytes stimulated with various pro-inflammatory
stimuli [29]. Taken together, these results support the use of IL-
36b in our experiments, notably in comparison with IL-1b.
In conclusion, our data further support the role of IL-36 in skin
inflammation and have identified human LC as a new IL-36 skin
target cell in addition to keratinocytes. Moreover, we have shown
for the first time that IL-36 can act on human macrophages, partic-
ularly M2 macrophages, and can drive them to a proinflammatory
phenotype. We also showed that human macrophage subsets
respond differently to IL-1 and IL-36 stimulation.Authorship
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